Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia
| Autor: | Therese Heinonen, D. Roger Illingworth, Anuradha S. Pappu, Gillian J. Pilcher, A. David Marais, Donald M. Black, Maritha J. Kotze, Firth Jc, Frederick J. Raal |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Urinary system Atorvastatin DNA Mutational Analysis Mevalonic Acid Mevalonic acid Hyperlipoproteinemia Type II Excretion chemistry.chemical_compound Basal (phylogenetics) In vivo Internal medicine medicine Humans Pyrroles Child Receptor Polymorphism Single-Stranded Conformational Cholesterol business.industry Anticholesteremic Agents Homozygote Cholesterol LDL DNA Prognosis Endocrinology Receptors LDL chemistry Heptanoic Acids Child Preschool Mutation Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Biomarkers medicine.drug |
| Zdroj: | Atherosclerosis. 150:421-428 |
| ISSN: | 0021-9150 |
| Popis: | Patients with homozygous familial hypercholesterolaemia (HoFH) have markedly elevated low density lipoprotein (LDL) cholesterol levels that are refractory to standard doses of lipid-lowering drug therapy. In the present study we evaluated the effect of atorvastatin on steady state concentrations of plasma lipids and mevalonic acid (MVA), as well as on 24-h urinary excretion of MVA in patients with well characterized HoFH. Thirty-five HoFH patients (18 males; 17 females) received 40 mg and then 80 mg atorvastatin/day. The dose of atorvastatin was increased further to 120 mg/day in 20 subjects and to 160 mg/day in 13 subjects who had not achieved LDL cholesterol goal, or in whom the dose of atorvastatin had not exceeded 2.5 mg/kg body wt per day. LDL cholesterol levels were reduced by 17% at the 40 mg/day and by 28% at the 80 mg/day dosage (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect